These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20212476)

  • 21. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 22. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 23. Take your partner by the hand..
    Smaglik P
    Nature; 2005 Jun; 435(7046):1281. PubMed ID: 15997477
    [No Abstract]   [Full Text] [Related]  

  • 24. Cetus and Chiron merge.
    Gershon D
    Nature; 1991 Aug; 352(6334):364. PubMed ID: 1861710
    [No Abstract]   [Full Text] [Related]  

  • 25. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

  • 26. Millennium and Aventis in unique pact.
    Fletcher L
    Nat Biotechnol; 2000 Aug; 18(8):817. PubMed ID: 10932140
    [No Abstract]   [Full Text] [Related]  

  • 27. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 28. Genentech grapples with direct offer.
    Huggett B
    Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
    [No Abstract]   [Full Text] [Related]  

  • 29. Row over industry link-up splits staff of Spanish lab.
    Fernandez Hermana LA
    Nature; 1994 Dec; 372(6507):586. PubMed ID: 7990935
    [No Abstract]   [Full Text] [Related]  

  • 30. UK firms buy into drug design skills of US start-ups.
    Nature; 1995 Feb; 373(6513):372. PubMed ID: 7830777
    [No Abstract]   [Full Text] [Related]  

  • 31. Bioentrepreneurship 2002: at home in your lab.
    Eisenhardt PE
    Anal Bioanal Chem; 2002 Jan; 372(1):9-11. PubMed ID: 11939216
    [No Abstract]   [Full Text] [Related]  

  • 32. In search of the élite.
    Gewin V
    Nature; 2003 Dec; 426(6967):713-7. PubMed ID: 14668879
    [No Abstract]   [Full Text] [Related]  

  • 33. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 34. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 36. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 37. Venter's departure sees Celera seek therapies.
    Dennis C
    Nature; 2002 Jan; 415(6871):461. PubMed ID: 11823816
    [No Abstract]   [Full Text] [Related]  

  • 38. Going it alone.
    Senior M
    Nat Biotechnol; 2014 May; 32(5):411-4. PubMed ID: 24811507
    [No Abstract]   [Full Text] [Related]  

  • 39. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 40. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.